BRISBANE, Calif., Oct. 3, 2014 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value, non-invasive surveillance solutions for transplant recipients, today announced that the Company's President and Chief Executive Officer, Peter Maag, will be presenting at the Biotechnology Industry Organization (BIO) Investor Forum at the Palace Hotel in San Francisco, CA on October 8, 2014 at 2:30pm PT/5:30pm ET.
A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available until January 15, 2015.
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. For more information, please visit: www.CareDxInc.com.
CONTACT: Westwicke Partners, LLC Leigh J. Salvo Principal Tel: 415-513-1281 firstname.lastname@example.org